NeuroCentrix has been providing TGA approved, outpatient esketamine (Spravato) treatment for patients with treatment resistant depression since November 2021.
In the recent March 2025 Federal Budget, it was announced that esketamine would be listed on the Pharmaceutical Benefit Scheme (PBS) effective 1st May 2025.
This decision will provide wider access for patients previously unable to access esketamine treatment.
NeuroCentrix currently has esketamine treatment clinics in Ballarat, Carlton, Dandenong, Toowong (QLD) and Launceston (TAS).
Eligibility
Patients who have trialled two or more oral antidepressants in their current episode of depression without a successful response may be eligible for this treatment.
About Esketamine Treatment
Esketamine (Spravato) is an antidepressant nasal spray.
Patients who are eligible for treatment will undergo the following treatment phases;
- Induction Phase – 2 sessions per week for 4 weeks
- Non-Induction Phase – 1 session per week for the following 24 weeks
Qualified medical and nursing staff will monitor the patient during the administration of the intranasal medication, and for two hours following administration. Patients are not permitted to drive home following treatment sessions, nor drive for a 24-hour period post-treatment.
If you would like to learn more about the esketamine (Spravato) treatment program and associated fees, please contact the NeuroCentrix Treatment Services team on (03) 9546 0009 and choose option 2 for Spravato or email: treatmentservices@neurocentrix.com.au
Appointments & Enquiries
Contacting us is your first step towards being eligible for one of our current research studies, gaining access to potential new treatments and scheduling an appointment for psychology or psychiatry consultation.
Neurocentrix Head Office
- Suite 3 Level 1, 19-21 Argyle Place South, Carlton 3053
- treatmentservices@neurocentrix.com.au
- 03 9546 0009
- 03 9959 8375
Request an appointment or send an enquiry
By entering your contact details, you agree to receive information from NeuroCentrix in the future that we believe may be relevant to you. Naturally, you can unsubscribe any time.